GAMMA Investing LLC Acquires 177 Shares of Illumina, Inc. (NASDAQ:ILMN)

GAMMA Investing LLC increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,096 shares of the life sciences company’s stock after purchasing an additional 177 shares during the period. GAMMA Investing LLC’s holdings in Illumina were worth $414,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its stake in shares of Illumina by 66.8% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock valued at $1,582,000 after acquiring an additional 4,797 shares in the last quarter. Tidal Investments LLC lifted its holdings in Illumina by 38.0% in the 3rd quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock worth $580,000 after purchasing an additional 1,226 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Illumina during the third quarter worth approximately $772,000. Finally, Sanctuary Advisors LLC grew its holdings in Illumina by 2.0% during the third quarter. Sanctuary Advisors LLC now owns 22,778 shares of the life sciences company’s stock valued at $3,192,000 after purchasing an additional 450 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ILMN. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. TD Cowen upped their price target on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. UBS Group increased their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Trading Up 3.9 %

Shares of ILMN opened at $136.01 on Monday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $21.57 billion, a PE ratio of -13.66 and a beta of 1.11. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The stock has a 50 day simple moving average of $141.86 and a 200-day simple moving average of $131.55.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the company posted $0.33 earnings per share. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, sell-side analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.